Shannon M Mumenthaler, PhD

Title(s)Assistant Professor of Medicine
Address12414 Exposition Blvd
Off Campus
Los Angeles CA 90064
Phone+1 310 228 6400
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Webber Foundation1999  - 2003Academic Scholarship
    University of California, Davis2000Alumni Scholarship
    University of California, Davis2002Howard Hughes Medical Institute Summer Honors Advanced Research Program (SHARP) Fellowship
    University of California, Davis2003Graduated with Honors
    University of California, Davis2003Undergraduate Student of the Year Award, Division of Biological Sciences
    University of California, Los Angeles2005  - 2006Life Sciences Core Curriculum Teaching Assistant Honorarium Award
    University of California, Los Angeles2006  - 2007Hortenese Fishbaugh Memorial Scholarship
    Third Annual National Cancer Institute Physical Sciences in Oncology Center2012Best Poster Award
    National Cancer Institute2013Junior Investigator Award
    USC2013Medical Faculty Women's Association Award

    Collapse Overview 
    Collapse Overview
    Dr. Mumenthaler is an Assistant Professor of Research Medicine at the CAMM. She received a B.S. in Genetics from UC Davis and a Ph.D. in Cellular and Molecular Pathology from UCLA. Although her primary scientific training is in cell biology, Dr. Mumenthaler applies a unique multidisciplinary approach toward her research program, partnering with mathematicians, clinicians, and engineers to explore critical areas in cancer. Her current research interests focus on the development of tools to better understand the evolutionary dynamics of tumor progression and drug resistance with specific investigations into the influence of microenvironmental selective pressures on tumor cell behavior. Toward this goal, Dr. Mumenthaler is closely collaborating with mathematical modelers to combine novel computational platforms with diverse experimental measurements to test and refine biological hypotheses and make clinically relevant predictions.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    A microengineered colon cancer-chip designed to investigate tumor-stromal interactions driving cancer progression
    NIH R01CA241137Dec 1, 2020 - Nov 30, 2025
    Role: Principal Investigator
    Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer
    NIH U01CA232137Sep 13, 2018 - Aug 31, 2023
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer. Mol Oncol. 2021 Oct; 15(10):2801-2817. Ghate NB, Kim S, Spiller E, Kim S, Shin Y, Rhie SK, Smbatyan G, Lenz HJ, Mumenthaler SM, An W. PMID: 34312968.
      View in: PubMed   Mentions:    Fields:    
    2. 3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration. Clin Transl Sci. 2021 Sep; 14(5):1659-1680. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Wang H, Brown PC, Chow ECY, Ewart L, Ferguson SS, Fitzpatrick S, Freedman BS, Guo GL, Hedrich W, Heyward S, Hickman J, Isoherranen N, Li AP, Liu Q, Mumenthaler SM, Polli J, Proctor WR, Ribeiro A, Wang JY, Wange RL, Huang SM. PMID: 33982436.
      View in: PubMed   Mentions: 1     Fields:    
    3. Human colorectal cancer-on-chip model to study the microenvironmental influence on early metastatic spread. iScience. 2021 May 21; 24(5):102509. Strelez C, Chilakala S, Ghaffarian K, Lau R, Spiller E, Ung N, Hixon D, Yoon AY, Sun RX, Lenz HJ, Katz JE, Mumenthaler SM. PMID: 34113836.
      View in: PubMed   Mentions:
    4. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. Eur J Cancer. 2021 Jun; 150:133-142. Arai H, Millstein J, Loupakis F, Stintzing S, Wang J, Battaglin F, Kawanishi N, Jayachandran P, Soni S, Zhang W, Mumenthaler SM, Cremolini C, Heinemann V, Falcone A, Lenz HJ. PMID: 33901792.
      View in: PubMed   Mentions:    Fields:    
    5. High-throughput microscopy reveals the impact of multifactorial environmental perturbations on colorectal cancer cell growth. Gigascience. 2021 Apr 19; 10(4). Chiang CT, Lau R, Ghaffarizadeh A, Brovold M, Vyas D, Juárez EF, Atala A, Agus DB, Soker S, Macklin P, Ruderman D, Mumenthaler SM. PMID: 33871006.
      View in: PubMed   Mentions: 1     Fields:    
    6. Clocking cancer: the circadian clock as a target in cancer therapy. Oncogene. 2021 May; 40(18):3187-3200. Battaglin F, Chan P, Pan Y, Soni S, Qu M, Spiller ER, Castanon S, Roussos Torres ET, Mumenthaler SM, Kay SA, Lenz HJ. PMID: 33846572.
      View in: PubMed   Mentions: 1     Fields:    
    7. RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Mol Cancer Ther. 2021 06; 20(6):1153-1160. Arai H, Cao S, Battaglin F, Wang J, Kawanishi N, Tokunaga R, Loupakis F, Stintzing S, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. PMID: 33785650.
      View in: PubMed   Mentions:    Fields:    
    8. Impact of tumor-parenchyma biomechanics on liver metastatic progression: a multi-model approach. Sci Rep. 2021 01 18; 11(1):1710. Wang Y, Brodin E, Nishii K, Frieboes HB, Mumenthaler SM, Sparks JL, Macklin P. PMID: 33462259.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. J Immunother Cancer. 2020 11; 8(2). Arai H, Xiao Y, Loupakis F, Kawanishi N, Wang J, Battaglin F, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Falcone A, Millstein J, Lenz HJ. PMID: 33172883.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance. Cancers (Basel). 2020 May 28; 12(6). Garvey CM, Lau R, Sanchez A, Sun RX, Fong EJ, Doche ME, Chen O, Jusuf A, Lenz HJ, Larson B, Mumenthaler SM. PMID: 32481658.
      View in: PubMed   Mentions:
    11. Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response. SLAS Discov. 2020 08; 25(7):744-754. Kim S, Choung S, Sun RX, Ung N, Hashemi N, Fong EJ, Lau R, Spiller E, Gasho J, Foo J, Mumenthaler SM. PMID: 32349587.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    12. A Perspective on Expanding Our Understanding of Cancer Treatments by Integrating Approaches from the Biological and Physical Sciences. SLAS Discov. 2020 08; 25(7):672-683. Fong EJ, Strelez C, Mumenthaler SM. PMID: 32297829.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. A truncating mutation in the autophagy gene UVRAG drives inflammation and tumorigenesis in mice. Nat Commun. 2019 12 12; 10(1):5681. Quach C, Song Y, Guo H, Li S, Maazi H, Fung M, Sands N, O'Connell D, Restrepo-Vassalli S, Chai B, Nemecio D, Punj V, Akbari O, Idos GE, Mumenthaler SM, Wu N, Martin SE, Hagiya A, Hicks J, Cui H, Liang C. PMID: 31831743.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    14. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. Int J Cancer. 2019 10 15; 145(8):2082-2090. Tokunaga R, Cao S, Naseem M, Battaglin F, Lo JH, Arai H, Loupakis F, Stintzing S, Puccini A, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. PMID: 30856283.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    15. Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. Eur J Cancer. 2019 04; 111:138-147. Puccini A, Loupakis F, Stintzing S, Cao S, Battaglin F, Togunaka R, Naseem M, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. PMID: 30852420.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    16. MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures. Anal Chem. 2018 12 18; 90(24):14156-14164. Liu X, Lukowski JK, Flinders C, Kim S, Georgiadis RA, Mumenthaler SM, Hummon AB. PMID: 30479121.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    17. mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer. Cancer Lett. 2018 10 10; 434:152-159. Chiang CT, Demetriou AN, Ung N, Choudhury N, Ghaffarian K, Ruderman DL, Mumenthaler SM. PMID: 30036610.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    18. PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. PLoS Comput Biol. 2018 02; 14(2):e1005991. Ghaffarizadeh A, Heiland R, Friedman SH, Mumenthaler SM, Macklin P. PMID: 29474446.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    19. Image-Based Tracking of Heterogeneous Single-Cell Phenotypes. Methods Mol Biol. 2018; 1745:47-63. Patsch K, Mumenthaler SM, Ruderman D. PMID: 29476462.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    20. MALDI Mass Spectrometry Imaging for Evaluation of Therapeutics in Colorectal Tumor Organoids. J Am Soc Mass Spectrom. 2018 03; 29(3):516-526. Liu X, Flinders C, Mumenthaler SM, Hummon AB. PMID: 29209911.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    21. Characterization of the mechanical properties of resected porcine organ tissue using optical fiber photoelastic polarimetry. Biomed Opt Express. 2017 Oct 01; 8(10):4663-4670. Hudnut AW, Babaei B, Liu S, Larson BK, Mumenthaler SM, Armani AM. PMID: 29082093.
      View in: PubMed   Mentions:
    22. Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques. J Vis Exp. 2017 06 30; (124). Garvey CM, Gerhart TA, Mumenthaler SM. PMID: 28715383.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Single cell dynamic phenotyping. Sci Rep. 2016 10 06; 6:34785. Patsch K, Chiu CL, Engeln M, Agus DB, Mallick P, Mumenthaler SM, Ruderman D. PMID: 27708391.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    24. Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21; 10(1):92. Juarez EF, Lau R, Friedman SH, Ghaffarizadeh A, Jonckheere E, Agus DB, Mumenthaler SM, Macklin P. PMID: 27655224.
      View in: PubMed   Mentions: 6     Fields:    
    25. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. PLoS Comput Biol. 2016 08; 12(8):e1005077. Lindsay D, Garvey CM, Mumenthaler SM, Foo J. PMID: 27560187.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    26. Dual transcript and protein quantification in a massive single cell array. Lab Chip. 2016 10 07; 16(19):3682-8. Park SM, Lee JY, Hong S, Lee SH, Dimov IK, Lee H, Suh S, Pan Q, Li K, Wu AM, Mumenthaler SM, Mallick P, Lee LP. PMID: 27546183.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    27. A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016 07 25; 6:29752. Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, Agus DB, Mallick P, Foo J, Mumenthaler SM. PMID: 27452732.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    28. Significance of duon mutations in cancer genomes. Sci Rep. 2016 06 08; 6:27437. Yadav VK, Smith KS, Flinders C, Mumenthaler SM, De S. PMID: 27272679.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Progress Towards Computational 3-D Multicellular Systems Biology. Adv Exp Med Biol. 2016; 936:225-246. Macklin P, Frieboes HB, Sparks JL, Ghaffarizadeh A, Friedman SH, Juarez EF, Jonckheere E, Mumenthaler SM. PMID: 27739051.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    30. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. PMID: 26244007.
      View in: PubMed   Mentions:
    31. Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma. PLoS One. 2015; 10(6):e0129433. Frieboes HB, Smith BR, Wang Z, Kotsuma M, Ito K, Day A, Cahill B, Flinders C, Mumenthaler SM, Mallick P, Simbawa E, Al-Fhaid AS, Mahmoud SR, Gambhir SS, Cristini V. PMID: 26061425.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    32. Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance. Biomarkers. 2015; 20(5):313-22. Yang-Kolodji G, Mumenthaler SM, Mehta A, Ji L, Tripathy D. PMID: 26329528.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    33. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. . 2014 Nov; 13(11):2607-17. Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM. PMID: 25143449.
      View in: PubMed   Mentions:
    34. The Need for Integrative Computational Oncology: An Illustrated Example through MMP-Mediated Tissue Degradation. Front Oncol. 2013; 3:194. Mumenthaler SM, D'Antonio G, Preziosi L, Macklin P. PMID: 23898463.
      View in: PubMed   Mentions:
    35. A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. Physical Sciences - Oncology Centers Network , Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH. PMID: 23618955.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    36. Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors. Evol Appl. 2013 Jan; 6(1):54-69. Foo J, Leder K, Mumenthaler SM. PMID: 23396647.
      View in: PubMed   Mentions:
    37. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 05; 8(6):2069-79. Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. PMID: 21995722.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    38. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. . 2009 Oct; 8(10):2882-93. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A. PMID: 19825806.
      View in: PubMed   Mentions:
    39. 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. J Cardiovasc Transl Res. 2009 Sep; 2(3):289-99. Villablanca AC, Tenwolde A, Lee M, Huck M, Mumenthaler S, Rutledge JC. PMID: 19654889.
      View in: PubMed   Mentions: 16     Fields:    Translation:Animals
    40. CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology. 2009 Apr 25; 387(1):59-66. Bernstein HB, Wang G, Plasterer MC, Zack JA, Ramasastry P, Mumenthaler SM, Kitchen CM. PMID: 19251297.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    41. Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate. 2008 Oct 01; 68(14):1561-9. Mumenthaler SM, Rozengurt N, Livesay JC, Sabaghian A, Cederbaum SD, Grody WW. PMID: 18663728.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    42. Expression of arginase II in prostate cancer. Int J Oncol. 2008 Feb; 32(2):357-65. Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW. PMID: 18202758.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells